Stammdaten
Ligand Pharmaceuticals Incorporated, ein Biopharmaka-Unternehmen, konzentriert sich auf die Entwicklung oder Übernahme von Technologien, die Pharmaunternehmen bei der Entdeckung und Entwicklung von Arzneimitteln weltweit unterstützen. Seine kommerziellen Programme umfassen Kyprolis und Evomela zur Behandlung des multiplen Myeloms; Veklury zur Behandlung von moderater bis schwerer COVID-19; Teriparatid-Injektionsprodukt gegen Osteoporose; Vaxneuvance zur Prävention invasiver Erkrankungen, die durch Streptococcus pneumoniae verursacht werden; und Pneumosil, ein Pneumokokken-Konjugatimpfstoff zur Prävention von Pneumokokken-Pneumonie bei Kindern. Das Unternehmen bietet auch Rylaze, eine rekombinante Erwinia-Asparaginase zur Behandlung akuter lymphoblastischer Leukämie oder lymphoblastischer Lymphome bei erwachsenen und pädiatrischen Patienten; und Nexterone, eine Captisol-Formulierung von Amiodaron; sowie Zulresso, eine Captisol-Formulierung von Brexanolon zur Behandlung von postpartaler Depression. Darüber hinaus bietet das Unternehmen Noxafil-IV, eine Captisol-Formulierung von Posaconazol zur intravenösen Anwendung; Duavee zur Behandlung von postmenopausaler Osteoporose; das Aziyo-Portfolio von kommerziellen Perikardmittel- und CanGaroo-Hüllenextrazellularmatrixprodukten; Exemptia gegen Autoimmunerkrankungen; Vivitra gegen Brustkrebs; Bryxta und Zybev gegen verschiedene Indikationen; und Minnebro zur Behandlung von Hypertonie. Die Partner- und Lizenzprogramme des Unternehmens, die sich in klinischer Entwicklung befinden, werden zur Behandlung von Krebs, Anfallsleiden, Diabetes, Herz-Kreislauf-Erkrankungen, Muskelschwund, Leber- und Nierenerkrankungen und anderen Erkrankungen verwendet. Darüber hinaus verkauft das Unternehmen Captisol-Materialien. Das Unternehmen wurde 1987 gegründet und hat seinen Sitz in Emeryville, Kalifornien. KI
Unternehmen & Branche
| Name | LIGAND PHARMACEUTICALS INC |
|---|---|
| Ticker | LGND |
| CIK | 0000886163 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Pharmazeutische Erzeugnisse |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 53220K215 |
|---|---|
| ISIN | US53220K2151 |
| Typ | Common Stock |
| Marktkapitalisierung | 5,94 Mrd. USD |
| KGV (P/E) | 49,03 |
| Beta | 1,17 |
| Dividendenrendite | 0,01 % |
Sitz & Kontakt
| Sitz (Inkorporation) | DE |
|---|---|
| Geschäftsadresse | 3911 SORRENTO VALLEY BLVD SUITE 110, 92121 SAN DIEGO, CA |
| Telefon | 858-550-7500 |
| EIN (IRS) | 77-0160744 |
Listing & Historie
| Listing-Börsen | Nasdaq · OTC · OTC · OTC · OTC |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
| Frühere Namen | LIGAND PHARMACEUTICALS (bis 1994) |
Bewertung
| KBV (P/B) | 5,84 vs. 3,15 (2021) ▲ |
|---|---|
| KUV (P/S) | 22,17 vs. 10,72 (2021) ▲ |
| EV/EBITDA | 77,2 vs. 16,6 (2021) ▲ |
| FCF-Rendite | 0,8 % vs. 2,7 % (2021) ▼ |
| Buyback-Rendite | 0,3 % vs. 0,0 % (2021) ▲ |
Qualität & Bilanz
| Operative Marge | 15,3 % vs. 43,0 % (2021) ▼ |
|---|---|
| Nettomarge | 46,4 % vs. 23,7 % (2021) ▲ |
| ROIC | 12,2 % vs. 6,9 % (2021) ▲ |
| Nettoverschuldung/EBITDA | -2,3 vs. -0,1 (2021) ▼ |
| Zinsdeckungsgrad | 8,7 vs. 5,3 (2021) ▲ |
| Forderungslaufzeit (DSO) | 81 T vs. 129 T (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | 3,15 | 1,90 | 1,79 | 2,47 | 3,68 | 5,96 | |
| KUV (P/S) | 10,72 | 5,77 | 9,55 | 12,25 | 13,95 | 21,65 | |
| EV/EBITDA | 16,6 | 20,1 | 25,5 | 156,9 | 47,7 | 45,6 | |
| FCF-Rendite | 2,7 % | 10,6 % | 3,7 % | 4,7 % | 1,3 % | 2,1 % | |
| Buyback-Rendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,4 % | – | |
| Qualität & Bilanz | |||||||
| Operative Marge | 43,0 % | 1,5 % | 9,1 % | -13,5 % | 15,3 % | 34,5 % | |
| Nettomarge | 23,7 % | -17,0 % | 39,7 % | -2,4 % | 46,4 % | 55,9 % | |
| ROIC | 6,9 % | -5,5 % | 7,4 % | -0,5 % | 12,2 % | 15,3 % | |
| Nettoverschuldung/EBITDA | -0,1 | -0,6 | -0,3 | -5,2 | -2,3 | -0,9 | |
| Zinsdeckungsgrad | 5,3 | 1,7 | 18,2 | -7,4 | 8,7 | 16,9 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
LGND
LIGAND PHARMACEUTICALS INC
Effektiv
Neutral
Handelsvolumen
Mittel
Insider
0,0
Keine Insider-Käufe
Institutionell
67,9
53 neu, 132 erhöht, 128,7M $ netto
Aktivist
34,9
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 270.04 | +10.2 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 218.02 | +36.5 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 298.79 | EMA50: 277.45 | |
| MACD-Histogramm | Bärisch | 10 % | -3.722 | Bearisch | |
| RSI(14) | Neutral | 10 % | 52.6 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 20.0 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 18.1 | +DI: 15.7 / −DI: 19.7 | |
| Z-Score(60) | Neutral | 5 % | 0.93 | In Range | |
| 52W-Position | Bullisch | 5 % | 86.9 % | Hoch 322.61 / Tief 131.58 | |
| Bollinger(20,2σ) | Neutral | 5 % | 20.1 % | Upper 326.30 / Mid 308.27 / Lower 290.25 | |
| LinReg-Slope(60) | Bullisch | 10 % | +1.9753 | R²=0.82 / annualisiert +189.7 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -600 | 317,15 | -190.291,02 | -109,1% | |
| 2026-07-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -700 | 313,46 | -219.420,18 | -125,8% | |
| 2026-07-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -900 | 315,78 | -284.199,75 | -162,9% | |
| 2026-07-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.081 | 312,28 | -337.572,95 | -193,5% | |
| 2026-07-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.119 | 311,72 | -348.814,68 | -199,9% | |
| 2026-07-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -100 | 314,58 | -31.457,88 | -18,0% | |
| 2026-07-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -104 | 310,20 | -32.261,04 | -18,5% | |
| 2026-07-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -396 | 308,99 | -122.359,49 | -70,1% | |
| 2026-06-16 | Sabba Stephen L | Director | Open Market Sale | -2.145 | 254,00 | -544.830,00 | -312,3% | |
| 2026-06-12 | Haas Jason | Director | Open Market Sale | -3.000 | 255,01 | -765.033,90 | -438,5% | |
| 2026-06-12 | Haas Jason | Director | Open Market Sale | -3.461 | 256,08 | -886.286,30 | -508,0% | |
| 2026-06-11 | Aryeh Jason | Director | Open Market Sale | -4.500 | 250,00 | -1.125.000,00 | -644,9% | |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open Market Sale | -697 | 249,53 | -173.924,22 | -99,7% | |
| 2026-06-10 | Aryeh Jason | Director | Open Market Sale | -500 | 250,00 | -125.000,00 | -71,7% | |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open Market Sale | -3.405 | 251,62 | -856.751,80 | -491,1% | |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open Market Sale | -257 | 247,22 | -63.536,49 | -36,4% | |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open Market Sale | -232 | 248,11 | -57.561,78 | -33,0% | |
| 2026-06-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -400 | 226,78 | -90.711,76 | -52,0% | |
| 2026-06-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -491 | 223,95 | -109.957,83 | -63,0% | |
| 2026-06-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -200 | 230,41 | -46.082,00 | -26,4% | |
| 2026-06-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.432 | 225,97 | -323.585,03 | -185,5% | |
| 2026-06-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.216 | 229,47 | -279.032,60 | -159,9% | |
| 2026-06-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -677 | 225,20 | -152.459,25 | -87,4% | |
| 2026-06-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -584 | 228,57 | -133.487,10 | -76,5% | |
| 2026-05-13 | KOZARICH JOHN W | Director | Open Market Sale | -1.575 | 223,50 | -352.012,50 | -201,8% | |
| 2026-05-12 | KOZARICH JOHN W | Director | Open Market Sale | -459 | 224,00 | -102.816,00 | -58,9% | |
| 2026-05-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -780 | 232,04 | -180.991,12 | -103,7% | |
| 2026-05-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -600 | 227,45 | -136.469,58 | -78,2% | |
| 2026-05-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -98 | 229,71 | -22.511,44 | -12,9% | |
| 2026-05-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -370 | 230,87 | -85.421,60 | -49,0% | |
| 2026-05-01 | KOZARICH JOHN W | Director | Open Market Sale | -165 | 231,87 | -38.258,07 | -21,9% | |
| 2026-05-01 | KOZARICH JOHN W | Director | Open Market Sale | -116 | 234,09 | -27.153,89 | -15,6% | |
| 2026-05-01 | KOZARICH JOHN W | Director | Open Market Sale | -105 | 232,57 | -24.419,89 | -14,0% | |
| 2026-05-01 | KOZARICH JOHN W | Director | Open Market Sale | -80 | 227,37 | -18.189,40 | -10,4% | |
| 2026-05-01 | KOZARICH JOHN W | Director | Open Market Sale | -1 | 229,87 | -229,87 | -0,1% | |
| 2026-05-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.420 | 232,92 | -330.749,24 | -189,6% | |
| 2026-05-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -932 | 228,75 | -213.198,45 | -122,2% | |
| 2026-05-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -800 | 234,02 | -187.214,16 | -107,3% | |
| 2026-04-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -337 | 204,50 | -68.917,38 | -39,5% | |
| 2026-04-01 | KOZARICH JOHN W | Director | Open Market Sale | -43 | 202,91 | -8.725,22 | -5,0% | |
| 2026-04-01 | KOZARICH JOHN W | Director | Open Market Sale | -79 | 202,42 | -15.991,36 | -9,2% | |
| 2026-04-01 | KOZARICH JOHN W | Director | Open Market Sale | -146 | 199,97 | -29.196,34 | -16,7% | |
| 2026-04-01 | KOZARICH JOHN W | Director | Open Market Sale | -159 | 204,26 | -32.477,77 | -18,6% | |
| 2026-04-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.302 | 199,72 | -260.038,17 | -149,1% | |
| 2026-04-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.238 | 200,94 | -248.767,31 | -142,6% | |
| 2026-04-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -963 | 203,22 | -195.702,59 | -112,2% | |
| 2026-04-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -700 | 201,90 | -141.327,97 | -81,0% | |
| 2026-04-01 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -460 | 198,85 | -91.470,68 | -52,4% | |
| 2026-04-01 | KOZARICH JOHN W | Director | Open Market Sale | -40 | 201,24 | -8.049,40 | -4,6% | |
| 2026-03-23 | Sabba Stephen L | Director | Open Market Sale | -1.000 | 207,87 | -207.872,70 | -119,2% | |
| 2026-03-11 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -3.057 | 225,00 | -687.825,00 | -394,3% | |
| 2026-03-06 | LAMATTINA JOHN L | Director | Open Market Sale | -2.161 | 200,76 | -433.842,36 | -248,7% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -699 | 198,71 | -138.894,93 | -79,6% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -93 | 200,62 | -18.657,89 | -10,7% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -100 | 197,70 | -19.769,54 | -11,3% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -100 | 199,01 | -19.900,50 | -11,4% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -200 | 204,17 | -40.834,00 | -23,4% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -207 | 199,96 | -41.390,89 | -23,7% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -300 | 201,70 | -60.510,00 | -34,7% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -340 | 206,37 | -70.164,78 | -40,2% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -460 | 205,18 | -94.381,88 | -54,1% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -612 | 207,01 | -126.689,45 | -72,6% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.142 | 208,87 | -238.532,28 | -136,7% | |
| 2026-03-04 | Reardon Andrew | Officer, CLO & Secretary | Open Market Sale | -1.446 | 208,12 | -300.939,06 | -172,5% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -53 | 200,08 | -10.604,12 | -6,1% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -668 | 203,63 | -136.023,97 | -78,0% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -697 | 202,79 | -141.342,75 | -81,0% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -698 | 201,09 | -140.363,54 | -80,5% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -743 | 204,74 | -152.125,46 | -87,2% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -950 | 201,73 | -191.640,27 | -109,9% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -1.457 | 205,79 | -299.841,42 | -171,9% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -1.588 | 206,89 | -328.541,96 | -188,3% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -2.457 | 207,91 | -510.823,08 | -292,8% | |
| 2026-03-04 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -3.413 | 208,80 | -712.620,75 | -408,5% | |
| 2026-03-03 | Sabba Stephen L | Director | Open Market Sale | -2.034 | 201,50 | -409.851,00 | -234,9% | |
| 2026-03-02 | KOZARICH JOHN W | Director | Open Market Sale | -204 | 199,69 | -40.736,64 | -23,4% | |
| 2026-03-02 | KOZARICH JOHN W | Director | Open Market Sale | -41 | 200,40 | -8.216,56 | -4,7% | |
| 2026-03-02 | KOZARICH JOHN W | Director | Open Market Sale | -50 | 202,54 | -10.126,94 | -5,8% | |
| 2026-03-02 | KOZARICH JOHN W | Director | Open Market Sale | -47 | 197,14 | -9.265,57 | -5,3% | |
| 2026-03-02 | KOZARICH JOHN W | Director | Open Market Sale | -42 | 203,57 | -8.549,94 | -4,9% | |
| 2026-03-02 | KOZARICH JOHN W | Director | Open Market Sale | -83 | 201,65 | -16.736,72 | -9,6% | |
| 2026-02-02 | KOZARICH JOHN W | Director | Open Market Sale | -23 | 195,61 | -4.498,92 | -2,6% | |
| 2026-02-02 | KOZARICH JOHN W | Director | Open Market Sale | -381 | 196,36 | -74.814,46 | -42,9% | |
| 2026-02-02 | KOZARICH JOHN W | Director | Open Market Sale | -39 | 191,00 | -7.449,00 | -4,3% | |
| 2026-02-02 | KOZARICH JOHN W | Director | Open Market Sale | -23 | 197,20 | -4.535,49 | -2,6% | |
| 2026-02-02 | KOZARICH JOHN W | Director | Open Market Sale | -1 | 192,18 | -192,18 | -0,1% | |
| 2026-01-02 | KOZARICH JOHN W | Director | Open Market Sale | -21 | 186,59 | -3.918,39 | -2,2% | |
| 2026-01-02 | KOZARICH JOHN W | Director | Open Market Sale | -207 | 190,27 | -39.385,95 | -22,6% | |
| 2026-01-02 | KOZARICH JOHN W | Director | Open Market Sale | -102 | 188,96 | -19.274,20 | -11,0% | |
| 2026-01-02 | KOZARICH JOHN W | Director | Open Market Sale | -91 | 187,95 | -17.103,78 | -9,8% | |
| 2026-01-02 | KOZARICH JOHN W | Director | Open Market Sale | -46 | 192,40 | -8.850,17 | -5,1% | |
| 2025-12-12 | Espinoza Octavio | Officer, Chief Financial Officer | Open Market Sale | -1.804 | 188,31 | -339.711,24 | -194,7% | |
| 2025-12-01 | KOZARICH JOHN W | Director | Open Market Sale | -47 | 195,80 | -9.202,54 | -5,3% | |
| 2025-12-01 | KOZARICH JOHN W | Director | Open Market Sale | -179 | 194,76 | -34.861,72 | -20,0% | |
| 2025-12-01 | KOZARICH JOHN W | Director | Open Market Sale | -92 | 197,72 | -18.189,95 | -10,4% | |
| 2025-12-01 | KOZARICH JOHN W | Director | Open Market Sale | -92 | 193,86 | -17.834,91 | -10,2% | |
| 2025-12-01 | KOZARICH JOHN W | Director | Open Market Sale | -30 | 200,02 | -6.000,46 | -3,4% | |
| 2025-12-01 | KOZARICH JOHN W | Director | Open Market Sale | -23 | 199,22 | -4.581,95 | -2,6% | |
| 2025-12-01 | KOZARICH JOHN W | Director | Open Market Sale | -4 | 196,35 | -785,38 | -0,5% | |
| 2025-11-07 | Gray Nancy Ryan | Director | Open Market Sale | -3.015 | 205,45 | -619.431,75 | -355,1% | |
| 2025-11-07 | LAMATTINA JOHN L | Director | Open Market Sale | -2.145 | 205,45 | -440.690,25 | -252,6% | |
| 2025-11-07 | LAMATTINA JOHN L | Director | Open Market Sale | -2.034 | 205,45 | -417.885,30 | -239,5% | |
| 2025-11-07 | Gray Nancy Ryan | Director | Open Market Sale | -3.556 | 205,45 | -730.580,20 | -418,8% | |
| 2025-11-03 | KOZARICH JOHN W | Director | Open Market Sale | -84 | 189,00 | -15.875,73 | -9,1% | |
| 2025-11-03 | KOZARICH JOHN W | Director | Open Market Sale | -207 | 191,25 | -39.588,63 | -22,7% | |
| 2025-11-03 | KOZARICH JOHN W | Director | Open Market Sale | -127 | 192,38 | -24.432,02 | -14,0% | |
| 2025-11-03 | KOZARICH JOHN W | Director | Open Market Sale | -49 | 190,26 | -9.322,64 | -5,3% | |
| 2025-10-01 | KOZARICH JOHN W | Director | Open Market Sale | -92 | 181,18 | -16.668,91 | -9,6% | |
| 2025-10-01 | KOZARICH JOHN W | Director | Open Market Sale | -196 | 178,41 | -34.967,40 | -20,0% | |
| 2025-10-01 | KOZARICH JOHN W | Director | Open Market Sale | -155 | 180,01 | -27.901,52 | -16,0% | |
| 2025-10-01 | KOZARICH JOHN W | Director | Open Market Sale | -24 | 177,60 | -4.262,52 | -2,4% | |
| 2025-09-23 | Aryeh Jason | Director | Open Market Sale | -4.418 | 170,41 | -752.849,73 | -431,5% | |
| 2025-09-23 | Aryeh Jason | Director | Open Market Sale | -4.628 | 170,96 | -791.222,78 | -453,5% | |
| 2025-09-23 | Aryeh Jason | Director | Open Market Sale | -954 | 171,92 | -164.015,21 | -94,0% | |
| 2025-09-02 | KOZARICH JOHN W | Director | Open Market Sale | -115 | 162,52 | -18.689,66 | -10,7% | |
| 2025-09-02 | KOZARICH JOHN W | Director | Open Market Sale | -85 | 164,25 | -13.961,08 | -8,0% | |
| 2025-09-02 | KOZARICH JOHN W | Director | Open Market Sale | -267 | 161,51 | -43.124,10 | -24,7% | |
| 2025-08-01 | KOZARICH JOHN W | Director | Open Market Sale | -467 | 131,88 | -61.585,86 | -35,3% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 2.961.923 | 0 | 2.961.923 | 591.347.927 | Neu | +100,0% | |
| CONGRESS ASSET MANAGEMENT CO | 659.911 | 504.637 | 155.274 | 208.591.268 | Aufgestockt | +30,8% | |
| Janus Henderson Group Ltd. | 1.009.891 | 0 | 1.009.891 | 201.622.937 | Neu | +100,0% | |
| Chicago Capital, LLC | 553.435 | 561.675 | -8.240 | 174.935.212 | Reduziert | -1,5% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 848.089 | 0 | 848.089 | 169.320.969 | Neu | +100,0% | |
| STATE STREET CORP | 778.856 | 0 | 778.856 | 155.498.600 | Neu | +100,0% | |
| Stephens Investment Management Group LLC | 475.609 | 494.670 | -19.061 | 150.335.249 | Reduziert | -3,9% | |
| FMR LLC | 596.127 | 0 | 596.127 | 119.016.815 | Neu | +100,0% | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 573.312 | 0 | 573.312 | 114.462.000 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 573.177 | 0 | 573.177 | 114.434.772 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 558.934 | 0 | 558.934 | 111.608.727 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 425.230 | 0 | 425.230 | 84.887.195 | Neu | +100,0% | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 411.543 | 0 | 411.543 | 82.164.560 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 381.111 | 0 | 381.111 | 76.088.811 | Neu | +100,0% | |
| LOOMIS SAYLES & CO L P | 353.209 | 0 | 353.209 | 70.518.177 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 306.111 | 0 | 306.111 | 61.115.061 | Neu | +100,0% | |
| VICTORY CAPITAL MANAGEMENT INC | 303.224 | 0 | 303.224 | 60.538.672 | Neu | +100,0% | |
| RICE HALL JAMES & ASSOCIATES, LLC | 283.567 | 0 | 283.567 | 56.614.152 | Neu | +100,0% | |
| Ranger Investment Management, L.P. | 267.943 | 0 | 267.943 | 53.494.820 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 254.158 | 0 | 254.158 | 50.742.645 | Neu | +100,0% | |
| NEW YORK STATE COMMON RETIREMENT FUND | 137.258 | 119.839 | 17.419 | 43.385.881 | Aufgestockt | +14,5% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 212.888 | 0 | 212.888 | 42.503.090 | Neu | +100,0% | |
| ASHFORD CAPITAL MANAGEMENT INC | 207.565 | 0 | 207.565 | 41.440.352 | Neu | +100,0% | |
| Private Capital Management, LLC | 201.381 | 0 | 201.381 | 40.205.717 | Neu | +100,0% | |
| VILLERE ST DENIS J & CO LLC | 188.874 | 0 | 188.874 | 37.708.694 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 182.887 | 0 | 182.887 | 36.513.390 | Neu | +100,0% | |
| MORGAN STANLEY | 167.229 | 0 | 167.229 | 33.387.355 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 157.865 | 0 | 157.865 | 31.517.680 | Neu | +100,0% | |
| Impax Asset Management Group plc | 152.444 | 0 | 152.444 | 30.435.445 | Neu | +100,0% | |
| Fiera Capital Corp | 135.312 | 0 | 135.312 | 27.015.040 | Neu | +100,0% | |
| Fisher Asset Management, LLC | 127.994 | 0 | 127.994 | 25.554.038 | Neu | +100,0% | |
| Russell Investments Group, Ltd. | 121.151 | 0 | 121.151 | 24.187.856 | Neu | +100,0% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 118.169 | 0 | 118.169 | 23.592.441 | Neu | +100,0% | |
| NOMURA HOLDINGS INC | 114.355 | 0 | 114.355 | 22.830.976 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 111.543 | 0 | 111.543 | 22.270.000 | Neu | +100,0% | |
| UBS Group AG | 104.580 | 0 | 104.580 | 20.879.398 | Neu | +100,0% | |
| Legal & General Group Plc | 97.660 | 0 | 97.660 | 19.497.821 | Neu | +100,0% | |
| NEXT CENTURY GROWTH INVESTORS LLC | 95.876 | 0 | 95.876 | 19.141.643 | Neu | +100,0% | |
| PRINCIPAL FINANCIAL GROUP INC | 95.716 | 0 | 95.716 | 19.109.700 | Neu | +100,0% | |
| Penn Capital Management Company, LLC | 95.456 | 0 | 95.456 | 19.077.735 | Neu | +100,0% | |
| Clark Capital Management Group, Inc. | 90.206 | 0 | 90.206 | 18.009.628 | Neu | +100,0% | |
| Aberdeen Group plc | 90.044 | 0 | 90.044 | 17.977.284 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 87.228 | 0 | 87.228 | 17.415.070 | Neu | +100,0% | |
| BANK OF MONTREAL /CAN/ | 86.183 | 0 | 86.183 | 17.206.436 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 84.901 | 0 | 84.901 | 16.950.385 | Neu | +100,0% | |
| FIRST TRUST ADVISORS LP | 80.401 | 0 | 80.401 | 16.052.059 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 77.273 | 0 | 77.273 | 15.427.556 | Neu | +100,0% | |
| SEI INVESTMENTS CO | 75.188 | 0 | 75.188 | 15.011.511 | Neu | +100,0% | |
| Context Capital Management, LLC | 46.000 | 0 | 46.000 | 14.540.140 | Neu | +100,0% | |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | 70.378 | 0 | 70.378 | 14.050.968 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| CONGRESS ASSET MANAGEMENT CO | 659.911 | 504.637 | +30,8% | 208.591.268 | 30,62 | 94 % | 9 Q |
| Chicago Capital, LLC | 553.435 | 561.675 | -1,5% | 174.935.212 | 25,68 | 100 % | 17 Q |
| Stephens Investment Management Group LLC | 475.609 | 494.670 | -3,9% | 150.335.249 | 22,06 | 0 % | 17 Q |
| NEW YORK STATE COMMON RETIREMENT FUND | 137.258 | 119.839 | +14,5% | 43.385.881 | 6,37 | 100 % | 17 Q |
| Context Capital Management, LLC | 46.000 | 0 | +100,0% | 14.540.140 | 2,13 | 100 % | 1 Q |
| Pembroke Management, LTD | 40.277 | 0 | +100,0% | 12.731.157 | 1,87 | 100 % | 1 Q |
| MOODY ALDRICH PARTNERS LLC | 28.160 | 14.675 | +91,9% | 8.901.094 | 1,31 | 44 % | 4 Q |
| ISTHMUS PARTNERS, LLC | 20.935 | 24.059 | -13,0% | 6.617.344 | 0,97 | 100 % | 17 Q |
| TD Waterhouse Canada Inc. | 19.625 | 0 | +100,0% | 6.121.719 | 0,90 | 100 % | 1 Q |
| WOODSTOCK CORP | 18.345 | 19.120 | -4,1% | 5.798.671 | 0,85 | 98 % | 17 Q |
| MOODY NATIONAL BANK TRUST DIVISION | 12.147 | 0 | +100,0% | 3.839.545 | 0,56 | 36 % | 1 Q |
| COOKSON PEIRCE & CO INC | 11.822 | 10.590 | +11,6% | 3.736.816 | 0,55 | 0 % | 9 Q |
| Linden Thomas Advisory Services, LLC | 9.935 | 16.669 | -40,4% | 3.140.354 | 0,46 | 0 % | 13 Q |
| Louisiana State Employees Retirement System | 8.800 | 8.700 | +1,1% | 2.781.592 | 0,41 | 100 % | 17 Q |
| Police & Firemen's Retirement System of New Jersey | 5.924 | 5.232 | +13,2% | 1.872.517 | 0,27 | 100 % | 7 Q |
| EQUITABLE TRUST CO | 5.640 | 5.035 | +12,0% | 1.782.748 | 0,26 | 20 % | 9 Q |
| YOUSIF CAPITAL MANAGEMENT, LLC | 5.451 | 5.363 | +1,6% | 1.723.007 | 0,25 | 25 % | 17 Q |
| Portside Wealth Group, LLC | 4.810 | 3.017 | +59,4% | 1.520.393 | 0,22 | 0 % | 9 Q |
| COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | 4.752 | 4.867 | -2,4% | 1.502.060 | 0,22 | 100 % | 17 Q |
| Atria Investments, Inc | 4.667 | 4.413 | +5,8% | 1.475.192 | 0,22 | 0 % | 9 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 113 | 2,2 | 683 |
| 31.03.2026 | ✓ | 354 | 22,7 | 4.447 |
| 31.12.2025 | ✓ | 345 | 21,3 | 3.942 |
| 30.09.2025 | ✓ | 315 | 37,0 | 3.670 |
| 30.06.2025 | ✓ | 267 | 19,2 | 2.136 |
| 31.03.2025 | ✓ | 257 | 20,1 | 2.028 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| NEXT CENTURY GROWTH INVESTORS LLC | 95.876 | 19.141.643 |
| PALISADE CAPITAL MANAGEMENT, LP | 20.525 | 4.097.816 |
| Moran Wealth Management, LLC | 19.306 | 3.854.443 |
| Walleye Capital LLC | 10.333 | 2.062.983 |
| Ishara Investments LP | 8.200 | 1.637.130 |
| MARSHALL WACE, LLP | 7.505 | 1.498.373 |
| Jefferies Financial Group Inc. | 7.315 | 1.460.440 |
| Squarepoint Ops LLC | 6.394 | 1.276.562 |
| Aquatic Capital Management LLC | 5.294 | 1.056.947 |
| Vident Advisory, LLC | 4.645 | 927.374 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| BESSEMER GROUP INC | 107.859 | 84.349 | +358.8 % | 21.535 |
| FRANKLIN RESOURCES INC | 573.177 | 77.017 | +15.5 % | 114.434.772 |
| GEODE CAPITAL MANAGEMENT, LLC | 558.934 | 65.345 | +13.2 % | 111.608.727 |
| VICTORY CAPITAL MANAGEMENT INC | 303.224 | 46.814 | +18.3 % | 60.538.672 |
| D. E. Shaw & Co., Inc. | 78.428 | 41.877 | +114.6 % | 15.658.150 |
| BANK OF AMERICA CORP /DE/ | 157.865 | 37.696 | +31.4 % | 31.517.680 |
| Qube Research & Technologies Ltd | 47.659 | 32.266 | +209.6 % | 9.515.119 |
| GW&K Investment Management, LLC | 149.501 | 32.069 | +27.3 % | 29.848 |
| SEI INVESTMENTS CO | 75.188 | 28.820 | +62.2 % | 15.011.511 |
| STATE STREET CORP | 778.856 | 27.651 | +3.7 % | 155.498.600 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 212.888 | -150.696 | -41.4 % | 42.503.090 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 20.529 | -106.225 | -83.8 % | 4.098.615 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 411.543 | -95.476 | -18.8 % | 82.164.560 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 573.312 | -70.781 | -11.0 % | 114.462.000 |
| GOLDMAN SACHS GROUP INC | 381.111 | -47.893 | -11.2 % | 76.088.811 |
| WELLS FARGO & COMPANY/MN | 84.901 | -47.735 | -36.0 % | 16.950.385 |
| F/m Investments LLC | 2.001 | -44.129 | -95.7 % | 398.684 |
| BANK OF MONTREAL /CAN/ | 86.183 | -39.880 | -31.6 % | 17.206.436 |
| UBS Group AG | 104.580 | -38.487 | -26.9 % | 20.879.398 |
| LOOMIS SAYLES & CO L P | 353.209 | -29.468 | -7.7 % | 70.518.177 |
Zusätzlich aktuell von 182 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 01.05.2026 | Vanguard Portfolio Management | Passiv (13G) | 5,56 % | 1.109.154 | Neu | |
| 01.05.2026 | Vanguard Capital Management | Passiv (13G) | 5,00 % | 997.637 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -10,76 pp | |
| 14.11.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 5,30 % | 1.042.378 | -0,20 pp | |
| 17.10.2025 | BlackRock, Inc. | Passiv (13G/A) | 14,50 % | 2.839.251 | -1,10 pp | |
| 14.08.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 5,50 % | 1.060.734 | +0,20 pp | |
| 14.05.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 5,30 % | 1.028.066 | -0,10 pp | |
| 14.02.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 5,40 % | 1.015.023 | Neu | |
| 05.02.2025 | BlackRock, Inc. | Passiv (13G/A) | 15,60 % | 2.945.939 | Neu | |
| 14.11.2024 | Janus Henderson Group plc | Passiv (13G/A) | 5,50 % | 1.009.094 | -2,20 pp | |
| 08.11.2024 | THE GOLDMAN SACHS GROUP, INC. (+1) | Passiv (13G/A) | 0,30 % | 52.350 | -6,50 pp | |
| 01.11.2024 | Macquarie Investment Management Business Trust (+2) | Passiv (13G/A) | 4,86 % | 887.275 | -0,80 pp | |
| 14.02.2024 | Macquarie Investment Management Business Trust (+2) | Passiv (13G) | 5,66 % | 987.248 | Neu | |
| 13.02.2024 | Janus Henderson Group plc | Passiv (13G/A) | 7,70 % | 1.343.154 | +0,30 pp | |
| 13.02.2024 | Janus Henderson Triton Fund | Passiv (13G/A) | 5,10 % | 897.906 | -0,20 pp | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 10,76 % | 1.876.514 | -0,15 pp | |
| 12.02.2024 | THE GOLDMAN SACHS GROUP, INC. (+1) | Passiv (13G) | 6,80 % | 1.181.931 | Neu | |
| 22.01.2024 | . BlackRock, Inc. | Passiv (13G/A) | 17,00 % | 2.962.094 | +0,50 pp | |
| 10.02.2023 | Janus Henderson Triton Fund | Passiv (13G/A) | 5,30 % | 897.906 | -0,70 pp | |
| 10.02.2023 | Janus Henderson Group plc | Passiv (13G/A) | 7,40 % | 1.255.273 | -1,20 pp | |
| 09.02.2023 | William Blair Investment Management, LLC | Passiv (13G/A) | 0,80 % | 141.128 | -7,60 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 10,91 % | 1.843.115 | +0,64 pp | |
| 06.02.2023 | : STATE STREET CORPORATION | Passiv (13G/A) | 3,85 % | 0 | -1,46 pp | |
| 26.01.2023 | . BlackRock, Inc. | Passiv (13G/A) | 16,50 % | 2.789.479 | 0,00 pp | |
| 20.01.2023 | . BlackRock, Inc. | Passiv (13G/A) | 16,50 % | 2.789.479 | +0,10 pp | |
| 14.02.2022 | Macquarie Investment Management Global Limited | Passiv (13G/A) | 0,00 % | 249 | Neu | |
| 14.02.2022 | Macquarie Investment Management Business Trust (+1) | Passiv (13G/A) | 3,74 % | 624.720 | Neu | |
| 14.02.2022 | Macquarie Group Limited | Passiv (13G/A) | 3,74 % | 624.969 | -1,94 pp | |
| 14.02.2022 | Cardinal Capital Management, LLC | Passiv (13G/A) | 1,00 % | 162.608 | -5,80 pp | |
| 11.02.2022 | : STATE STREET CORPORATION | Passiv (13G/A) | 5,31 % | 0 | -1,94 pp | |
| 10.02.2022 | Janus Henderson Group plc | Passiv (13G/A) | 8,60 % | 1.441.085 | -1,40 pp | |
| 10.02.2022 | Janus Henderson Triton Fund | Passiv (13G/A) | 6,00 % | 1.010.358 | -0,70 pp | |
| 10.02.2022 | The Vanguard Group | Passiv (13G/A) | 10,27 % | 1.716.735 | -0,06 pp | |
| 10.02.2022 | William Blair Investment Management, LLC | Passiv (13G/A) | 8,40 % | 1.400.341 | +0,70 pp | |
| 27.01.2022 | . BlackRock, Inc. | Passiv (13G/A) | 16,40 % | 2.742.808 | 0,00 pp | |
| 25.01.2022 | . BlackRock, Inc. | Passiv (13G/A) | 16,40 % | 2.742.808 | +4,20 pp | |
| 12.10.2021 | The Vanguard Group | Passiv (13G/A) | 10,33 % | 1.722.291 | +1,26 pp |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 29.05.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 03.03.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 15.01.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 05.01.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 51.722.000 $ | -13.345.000 $ | -0,67 $ | 1.532.105.000 $ | 997.322.000 $ |
| 2025-12-31 | 10-K | 268.087.000 $ | 124.453.000 $ | 6,13 $ | 1.560.637.000 $ | 1.017.212.000 $ |
| 2025-09-30 | 10-Q | 115.461.000 $ | 117.273.000 $ | 5,68 $ | 1.476.772.000 $ | 950.171.000 $ |
| 2025-06-30 | 10-K | 53.100.000 $ | – | – | – | – |
| 2025-06-30 | 10-Q | 53.100.000 $ | 4.847.000 $ | 0,24 $ | 948.604.000 $ | 827.313.000 $ |
| 2025-03-31 | 10-Q | 45.333.000 $ | -42.451.000 $ | -2,21 $ | 905.435.000 $ | 795.594.000 $ |
| 2024-12-31 | 10-K | 167.133.000 $ | -4.032.000 $ | -0,22 $ | 941.774.000 $ | 830.439.000 $ |
| 2024-09-30 | 10-Q | 51.812.000 $ | -7.172.000 $ | -0,39 $ | 954.866.000 $ | 841.178.000 $ |
| 2024-06-30 | 10-Q | 41.531.000 $ | -51.911.000 $ | -2,88 $ | 866.405.000 $ | 775.198.000 $ |
| 2024-03-31 | 10-Q | 30.978.000 $ | 86.139.000 $ | 4,75 $ | 913.869.000 $ | 806.521.000 $ |
| 2023-12-31 | 10-K | 131.314.000 $ | 52.154.000 $ | 2,94 $ | 787.216.000 $ | 700.913.000 $ |
| 2023-09-30 | 10-Q | 32.868.000 $ | -10.273.000 $ | -0,59 $ | 769.226.000 $ | 667.896.000 $ |
| 2023-06-30 | 10-Q | 26.366.000 $ | 2.290.000 $ | 0,13 $ | 758.105.000 $ | 664.892.000 $ |
| 2023-03-31 | 10-Q | 43.979.000 $ | 41.949.000 $ | 2,33 $ | 811.076.000 $ | 646.317.000 $ |
| 2022-12-31 | 10-K | 196.245.000 $ | -33.361.000 $ | -1,98 $ | 762.668.000 $ | 597.485.000 $ |
| 2022-09-30 | 10-Q | 59.221.000 $ | 404.000 $ | 0,02 $ | 1.050.605.000 $ | 816.298.000 $ |
| 2022-06-30 | 10-Q | 50.126.000 $ | -895.000 $ | -0,05 $ | 1.076.288.000 $ | 802.365.000 $ |
| 2022-03-31 | 10-Q | 36.516.000 $ | -15.385.000 $ | -0,91 $ | 1.105.184.000 $ | 793.192.000 $ |
| 2021-12-31 | 10-K | 241.544.000 $ | 57.138.000 $ | 3,31 $ | 1.297.590.000 $ | 821.159.000 $ |
| 2021-09-30 | 10-Q | 64.835.000 $ | 13.723.000 $ | 0,80 $ | 1.273.656.000 $ | 812.066.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Royalty | 161,0 Mio. | 108,8 Mio. | 83,9 Mio. | 72,5 Mio. | 48,9 Mio. | 60,1 % | +48,0% | |
| Intangible Royalty Assets | 132,5 Mio. | 95,3 Mio. | – | – | – | 49,4 % | +39,0% | |
| Contract Revenue | 66,9 Mio. | 27,5 Mio. | 19,0 Mio. | 19,2 Mio. | 64,0 Mio. | 24,9 % | +143,4% | |
| Contract Revenue And Income | 66,9 Mio. | – | – | – | – | 24,9 % | Neu | |
| Income From Divestiture Transactions | 53,1 Mio. | – | – | – | – | 19,8 % | Neu | |
| Material Sales Captisol | 40,2 Mio. | 30,9 Mio. | 28,4 Mio. | 104,5 Mio. | 164,3 Mio. | 15,0 % | +30,2% | |
| Material Sales Captisol Core | 40,2 Mio. | 30,9 Mio. | 28,4 Mio. | 16,4 Mio. | – | 15,0 % | +30,2% | |
| Royalty Kyprolis | 35,5 Mio. | 38,4 Mio. | 35,6 Mio. | 30,1 Mio. | 27,5 Mio. | 13,3 % | -7,4% | |
| Filspari | 32,0 Mio. | 12,2 Mio. | – | – | – | 11,9 % | +162,5% | |
| Financial Royalty Assets | 28,5 Mio. | 13,4 Mio. | – | – | – | 10,6 % | +111,7% | |
| QARZIBA | 23,7 Mio. | – | – | – | – | 8,9 % | Neu | |
| Royalty Rylaze | 13,4 Mio. | 13,7 Mio. | 13,5 Mio. | 8,8 Mio. | – | 5,0 % | -2,9% | |
| Royalty Other | 10,4 Mio. | 8,9 Mio. | 13,5 Mio. | 7,6 Mio. | 11,4 Mio. | 3,9 % | +15,9% | |
| Capvaxive | 10,1 Mio. | – | – | – | – | 3,8 % | Neu | |
| Ohtuvayre | 9,8 Mio. | – | – | – | – | 3,6 % | Neu | |
| Royalty Teriparatide Injection | 8,1 Mio. | 8,2 Mio. | 11,1 Mio. | 15,8 Mio. | – | 3,0 % | -0,9% | |
| Vaxneuvance | 7,4 Mio. | 5,2 Mio. | – | – | – | 2,8 % | +42,8% | |
| License Fees | 7,0 Mio. | 1,9 Mio. | 217.000 | 2,8 Mio. | 5,1 Mio. | 2,6 % | +259,5% | |
| Service | 6,8 Mio. | 25,5 Mio. | 615.000 | 1,1 Mio. | 23,7 Mio. | 2,5 % | -73,3% | |
| Royalty Evomela | 5,9 Mio. | 8,7 Mio. | 10,2 Mio. | 10,2 Mio. | 10,1 Mio. | 2,2 % | -31,5% | |
| Financial Royalty Other | 4,7 Mio. | – | – | – | – | 1,8 % | Neu | |
| Contract Revenue And Other Income | – | 27,5 Mio. | – | – | – | – | – | |
| Milestone | – | – | 16,8 Mio. | 9,2 Mio. | 28,7 Mio. | – | – | |
| License Fees Milestones And Other Product Other | – | – | 1,4 Mio. | 6,1 Mio. | 6,4 Mio. | – | – | |
| Material Sales Captisol COVID | – | – | – | 88,1 Mio. | – | – | – |
Quartalsverlauf
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Contract Revenue And Other Income | 58,2 Mio. | 2,9 Mio. | 4,4 Mio. | 13,8 Mio. | 10,9 Mio. | 2,7 Mio. | 50,4 % | +320,3% | |
| Income From Divestiture Transactions | 53,1 Mio. | – | – | – | – | – | 46,0 % | Neu | |
| Royalty | 46,6 Mio. | 36,4 Mio. | 27,5 Mio. | 31,7 Mio. | 23,2 Mio. | 19,1 Mio. | 40,3 % | +46,9% | |
| Intangible Royalty Assets | 40,2 Mio. | 30,1 Mio. | 21,6 Mio. | 26,6 Mio. | 22,6 Mio. | 18,4 Mio. | 34,8 % | +51,3% | |
| Kyprolis | 11,6 Mio. | 8,8 Mio. | 4,7 Mio. | 11,6 Mio. | 9,0 Mio. | 6,6 Mio. | 10,1 % | +0,2% | |
| Material Sales Captisol | 10,7 Mio. | 8,3 Mio. | 13,5 Mio. | 6,3 Mio. | 7,5 Mio. | 9,2 Mio. | 9,2 % | +70,6% | |
| Filspari | 9,1 Mio. | 6,6 Mio. | 5,3 Mio. | 3,2 Mio. | 2,4 Mio. | 1,8 Mio. | 7,9 % | +183,2% | |
| Financial Royalty Assets | 6,4 Mio. | 6,3 Mio. | 5,9 Mio. | 5,2 Mio. | 559.000 | 738.000 | 5,6 % | +24,6% | |
| QARZIBA | 6,0 Mio. | 5,9 Mio. | 5,4 Mio. | – | – | – | 5,2 % | Neu | |
| Contract And Revenue Income Other | 5,0 Mio. | 1,0 Mio. | – | – | – | 1,9 Mio. | 4,3 % | Neu | |
| Rylaze | 3,6 Mio. | 2,9 Mio. | 3,1 Mio. | 3,9 Mio. | 3,2 Mio. | 3,0 Mio. | 3,1 % | -8,5% | |
| Royalty Intangible Other | 3,4 Mio. | 5,4 Mio. | 4,0 Mio. | – | – | – | 3,0 % | Neu | |
| Capvaxive | 3,2 Mio. | – | – | – | – | – | 2,8 % | Neu | |
| Ohtuvayre | 2,7 Mio. | – | – | – | – | – | 2,4 % | Neu | |
| Teriparatide Injection | 2,6 Mio. | 2,3 Mio. | 1,2 Mio. | 2,4 Mio. | 2,1 Mio. | 2,0 Mio. | 2,3 % | +10,8% | |
| Vaxneuvance | 2,0 Mio. | 2,6 Mio. | 1,3 Mio. | 1,5 Mio. | 1,1 Mio. | 1,4 Mio. | 1,8 % | +39,1% | |
| Evomela | 1,9 Mio. | 1,5 Mio. | 2,0 Mio. | 1,7 Mio. | 2,7 Mio. | 1,4 Mio. | 1,6 % | +8,4% | |
| Financial Royalty Other | 449.000 | 428.000 | 460.000 | – | – | – | 0,4 % | Neu | |
| Contract Revenue | 131.000 | – | – | – | – | – | 0,1 % | Neu | |
| Milestone And Other | – | 1,9 Mio. | 4,4 Mio. | 13,8 Mio. | 10,9 Mio. | 727.000 | – | – | |
| Royalty Other | – | – | – | 2,3 Mio. | 2,0 Mio. | 2,2 Mio. | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 08.05.2026 | 51,7 Mio. USD | -0,67 |
| Q3 2025 | 30.09.2025 | 07.11.2025 | 115,5 Mio. USD | 5,68 |
| Q2 2025 | 30.06.2025 | 08.08.2025 | 47,6 Mio. USD | 0,24 |
| Q1 2025 | 31.03.2025 | 09.05.2025 | 45,3 Mio. USD | -2,21 |
| Q3 2024 | 30.09.2024 | 08.11.2024 | 51,8 Mio. USD | -0,39 |
| Q2 2024 | 30.06.2024 | 07.08.2024 | 41,5 Mio. USD | -2,88 |
| Q1 2024 | 31.03.2024 | 08.05.2024 | 31,0 Mio. USD | 4,75 |
| Q3 2023 | 30.09.2023 | 09.11.2023 | 32,9 Mio. USD | -0,59 |
| Q2 2023 | 30.06.2023 | 09.08.2023 | 26,4 Mio. USD | 0,13 |
Dividenden
Dividende je Aktie (Jahr, SEC-XBRL)
| Jahr | DPS |
|---|---|
| 2007 | 2,5000 |
Beträge aus SEC-XBRL, Termine aus 8-K Item 8.01 (regelbasiert extrahiert, KI als Fallback), ohne Gewähr.
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 08.05.2026 | 10-Q | 31.03.2026 | 38 Tage | SEC » |
| 27.02.2026 | 10-K | 31.12.2025 | 58 Tage | SEC » |
| 07.11.2025 | 10-Q | 30.09.2025 | 38 Tage | SEC » |
| 08.08.2025 | 10-Q | 30.06.2025 | 39 Tage | SEC » |
| 09.05.2025 | 10-Q | 31.03.2025 | 39 Tage | SEC » |
| 28.02.2025 | 10-K | 31.12.2024 | 59 Tage | SEC » |
| 08.11.2024 | 10-Q | 30.09.2024 | 39 Tage | SEC » |
| 07.08.2024 | 10-Q | 30.06.2024 | 38 Tage | SEC » |
| 08.05.2024 | 10-Q | 31.03.2024 | 38 Tage | SEC » |
| 29.02.2024 | 10-K | 31.12.2023 | 60 Tage | SEC » |
| 09.11.2023 | 10-Q | 30.09.2023 | 40 Tage | SEC » |
| 09.08.2023 | 10-Q | 30.06.2023 | 40 Tage | SEC » |
| 08.05.2023 | 10-Q | 31.03.2023 | 38 Tage | SEC » |
| 28.02.2023 | 10-K | 31.12.2022 | 59 Tage | SEC » |
| 08.11.2022 | 10-Q | 30.09.2022 | 39 Tage | SEC » |
| 09.08.2022 | 10-Q | 30.06.2022 | 40 Tage | SEC » |
| 09.05.2022 | 10-Q | 31.03.2022 | 39 Tage | SEC » |
| 28.02.2022 | 10-K | 31.12.2021 | 59 Tage | SEC » |
| 09.11.2021 | 10-Q | 30.09.2021 | 40 Tage | SEC » |
| 03.08.2021 | 10-Q | 30.06.2021 | 34 Tage | SEC » |
| 06.05.2021 | 10-Q | 31.03.2021 | 36 Tage | SEC » |
| 24.02.2021 | 10-K | 31.12.2020 | 55 Tage | SEC » |
| 06.11.2020 | 10-Q | 30.09.2020 | 37 Tage | SEC » |
| 07.08.2020 | 10-Q | 30.06.2020 | 38 Tage | SEC » |
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 18.05.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 28.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 27.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 21.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 21.04.2026 | HV-Einladung | 05.06.2026 Jahres-HV | 16.04.2026 | DEF 14A | SEC » |
| 22.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 22.04.2025 | HV-Einladung | 06.06.2025 Jahres-HV | 17.04.2025 | DEF 14A | SEC » |
| 03.06.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 09.05.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 25.04.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 25.04.2024 | HV-Einladung | 14.06.2024 Jahres-HV | 19.04.2024 | DEF 14A | SEC » |
| 20.04.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 20.04.2023 | HV-Einladung | 09.06.2023 Jahres-HV | 14.04.2023 | DEF 14A | SEC » |
| 22.04.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 22.04.2022 | HV-Einladung | 10.06.2022 Jahres-HV | 11.04.2022 | DEF 14A | SEC » |
| 18.05.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 23.04.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 23.04.2021 | HV-Einladung | 04.06.2021 Jahres-HV | 13.04.2021 | DEF 14A | SEC » |
| 12.11.2020 | HV-Einladung | 15.12.2020 a.o. HV | 05.11.2020 | DEF 14A | SEC » |
| 30.10.2020 | Vorläufig | — | — | PRE 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Übernahmen & Fusionen (M&A)
M&A-relevante SEC-Filings der letzten sechs Jahre: Übernahmeangebote (Tender Offers), Fusionen (425/S-4), Aktienrückkauf-Angebote (Self-Tender) und Going-Private-Transaktionen. Geführt nach dem einreichenden Emittenten.
| Datum (US) | Kategorie | Form | Deal-Konditionen | SEC |
|---|---|---|---|---|
| 03.10.2022 | Fusion | 425 | Ziel: Ligand Pharmaceuticals Incorporated · Umtausch 4,9 Akt./Ziel-Aktie | SEC » |
| 24.08.2022 | Fusion | 425 | – | SEC » |
| 21.06.2022 | Fusion | 425 | Ziel: OmniAb, Inc. | SEC » |
| 05.05.2022 | Fusion | 425 | – | SEC » |
| 24.03.2022 | Fusion | 425 | Ziel: OmniAb, Inc. | SEC » |
| 23.03.2022 | Fusion | 425 | Ziel: OmniAb, Inc. | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Deal-Konditionen aus dem Dokument extrahiert (Tender: SC TO-T/-I/SC 14D9; Fusion: 425/S-4 — Gegenpartei + Umtauschverhältnis), ohne Gewähr — Original siehe SEC-Link.
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (09.06.2026)
HOCH Abgang Schlüsselpersonen (09.06.2026)
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 25.06.2026 | Volltext-Klassifikation | Fortführungszweifel | EXTREM | SEC | concern |
| 09.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 02.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 17.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 27.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 14.12.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 05.12.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 04.11.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 02.08.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 29.06.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 13.06.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 27.01.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.07.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 28.01.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 16.12.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 14.07.2026 | M&A abgeschlossen | 0,30 | 75 | Ligand Pharmaceuticals Inc. hat den M&A-Vertrag mit HoldCo abgeschlossen, wobei jede XOMA-Royalty-Aktie in $39 plus CVR umgewandelt wurde. V… 🔒 | SEC |
| 25.06.2026 | Finanzierung/Anleihe | 0,15 | 65 | Ligand Pharmaceuticals platziert private Schuldverschreibungen (Notes) unter Section 4(a)(2) des Securities Act an qualifizierte institution… 🔒 | SEC |
| 09.06.2026 | HV-Abstimmung | 0,10 | 35 | Aktionäre der Ligand Pharmaceuticals genehmigten auf der Jahresversammlung vom 5. Juni 2026 die Wahl von acht Vorstandsmitgliedern und die Ä… 🔒 | SEC |
| 07.05.2026 | Quartalszahlen | 0,00 | 50 | Ligand Pharmaceuticals gibt Quartalsergebnisse für Q1 2026 (bis 31. März 2026) bekannt. Die Ergebnisse werden in einer beigelegten Pressemit… 🔒 | SEC |
| 30.04.2026 | Wesentliche Vereinbarung | -0,25 | 45 | Ligand Pharmaceuticals kündigte am 24. April 2026 das TR-Beta-Programm, eine Lizenzvereinbarung mit Viking Therapeutics von 2014. Die wirtsc… 🔒 | SEC |
| 26.02.2026 | Quartalszahlen | 0,00 | 50 | Ligand Pharmaceuticals kündigte Finanzergebnisse für Q4 2025 an. Pressemitteilung liegt als Exhibit bei. | SEC |